about the author

Endpoints Contributor

help@endpts.com

author articles

Cell and Gene Con­tract Man­u­fac­tur­ers Must Em­brace Dig­i­ti­za­tion

5 years ago

Aus­tralia, home to a world-class ear­ly phase clin­i­cal tri­al ecosys­tem

5 years ago

Trans­port Sim­u­la­tion Test­ing for Your Ther­a­py is the Best Way to As­sure FDA Ex­pe­dit­ed Pro­gram Ap­proval

5 years ago

$48 Bil­lion Is Lost to Avoid­able Ex­per­i­ment Ex­pen­di­ture Every Year

5 years ago

BiTE® Plat­form and the Evo­lu­tion To­ward Off-The-Shelf Im­muno-On­col­o­gy Ap­proach­es

5 years ago

Biotech Voic­es: Coro­n­avirus will change biotech re­search with re­mote col­lab­o­ra­tions

5 years ago
Biotech Voices
Coronavirus

How Aus­tralia De­liv­ers Rapid Start-up and 43.5% Re­bate for Ear­ly Phase On­col­o­gy Tri­als

5 years ago

De­cen­tral­ized Clin­i­cal Tri­als: The fu­ture of clin­i­cal tri­als is now

5 years ago

A Fast Way to Curb Drug De­vel­op­ment Costs? Make Fail­ure a Strat­e­gy.

5 years ago

Tak­ing Ac­tion to En­sure Clin­i­cal Tri­al Progress Dur­ing COVID-19

6 years ago

Five strate­gies for mit­i­gat­ing the im­pact of COVID-19 on clin­i­cal tri­als

6 years ago

Covid-19 vac­cine track­er up­dat­ed to in­clude GSK/Sanofi col­lab­o­ra­tion

6 years ago
FDA+
Coronavirus

Covid-19 Track­er up­dates vac­cine can­di­dates

6 years ago
FDA+
Coronavirus

Drug dis­cov­ery in the age of coro­n­avirus

6 years ago
Biotech Voices
Coronavirus

Ven­ture Cap­i­tal as a Strate­gic Part­ner: Fu­el­ing In­no­va­tion be­yond Fi­nance

6 years ago

Ad­dress­ing Key Chal­lenges of Lipid-Me­di­at­ed De­liv­ery Sys­tems for mR­NA through In­no­va­tion

6 years ago

Zhi­meng Bio­phar­ma An­nounces the First-in-Hu­man Dos­ing in Phase I Clin­i­cal Tri­al of ZM-H1505R De­signed for the ...

6 years ago

A New Fron­tier: The In­ner Ear

6 years ago

2019 Trin­i­ty Drug In­dex Eval­u­ates Ac­tu­al Com­mer­cial Per­for­mance of Nov­el Drugs Ap­proved in 2016

6 years ago

How to cap­i­talise on a lean launch

6 years ago

Turn­ing the cor­ner on treat­ing the root cause of sick­le cell dis­ease

6 years ago

Es­sen­tial cri­te­ria bio­phar­ma­ceu­ti­cal in­vestors seek when eval­u­at­ing com­pounds and com­pa­nies

6 years ago

In­vent­ing Med­i­cine by Ac­cess­ing the Hid­den Trea­sure in the Hu­man Mi­cro­bio­me’s Dark Mat­ter

6 years ago

Bio­phar­ma has aban­doned an­tibi­ot­ic de­vel­op­ment. Here’s why we did, too.

6 years ago
Biotech Voices
First page Previous page 6789101112 Next page Last page
A service from the Financial Times